Archon Biosciences raised $20M in seed financing led by Madrona Ventures to advance its innovative Antibody Cage technology for drug development.

Oct 30, 2024•about 1 year ago

Amount Raised

$20 Million

Round Type

seed

SeattleTherapeuticsArtificial IntelligenceBiotechnologyHealth Care

Investors

Cornucopian CapitalAlexandria Venture InvestmentsPack VenturesWrf CapitalSahsen VenturesDumac Inc.Madrona Ventures

Description

Archon Biosciences, a biotechnology company, has emerged from stealth with $20 million in seed financing. The funding, led by Madrona Ventures, will be used to enhance their novel class of biologics and develop their proprietary protein design platform.

Company Information

Company

Archon Biosciences

Location

Seattle, Washington, United States

About

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends